[HTML][HTML] Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
Z Hu, M Li, Z Chen, C Zhan, Z Lin… - … Lung Cancer Research, 2019 - ncbi.nlm.nih.gov
There were many clinical studies on lung cancer in 2018. In particular, significant progress
has been made in immunotherapy and targeted therapy. Whether in small cell lung cancer …
has been made in immunotherapy and targeted therapy. Whether in small cell lung cancer …
EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations
ES Kim, B Melosky, K Park, N Yamamoto… - Future …, 2021 - Future Medicine
Few data are available that have compared outcomes with different EGFR tyrosine kinase
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …
inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell …
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
K Park, D Wan-Teck Lim, I Okamoto… - … advances in medical …, 2019 - journals.sagepub.com
Afatinib is an ErbB family blocker that is approved for the treatment of epidermal growth
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …
factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pivotal …
Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
S Wang, J Li - OncoTargets and therapy, 2019 - Taylor & Francis
The discovery that mutations in the EGFR gene are present in up to 50% of patients with
lung adenocarcinoma, and the development of highly efficacious EGFR tyrosine kinase …
lung adenocarcinoma, and the development of highly efficacious EGFR tyrosine kinase …
Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non‐small‐cell lung cancer harboring EGFR mutations: results from a real …
T Kim, TW Jang, CM Choi, MH Kim, SY Lee… - Cancer …, 2021 - Wiley Online Library
Objectives The optimal sequence for the administration of epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) for treating non‐small cell lung cancer (NSCLC) is …
(EGFR) tyrosine kinase inhibitors (TKIs) for treating non‐small cell lung cancer (NSCLC) is …
[HTML][HTML] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a standard of
care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small …
care in the first-line treatment of patients with EGFR mutation-positive metastatic non-small …
Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non–small-cell lung cancer
RGP Gijtenbeek, RAM Damhuis, HJM Groen… - Clinical lung cancer, 2020 - Elsevier
Background Only a few randomized trials directly compared the relative efficacy of tyrosine
kinase inhibitors (TKIs) in patients with advanced epidermal growth factor receptor (EGFR) …
kinase inhibitors (TKIs) in patients with advanced epidermal growth factor receptor (EGFR) …
Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of …
HC Chang, KT Huang, CC Tseng, YM Chen… - Thoracic …, 2023 - Wiley Online Library
Background The comparative efficacies of different generation tyrosine kinase inhibitors
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
(TKIs) in epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung …
[HTML][HTML] Real-world treatment patterns, epidermal growth factor receptor (EGFR) testing and outcomes in EGFR-mutated advanced non-small cell lung cancer patients …
K Cuppens, L Lodewyckx, I Demedts… - Drugs-real world …, 2021 - Springer
Background Treatment of patients with epidermal growth factor receptor-mutated (EGFRm)
non-small cell lung cancer (NSCLC) continues to evolve expeditiously. Objectives This …
non-small cell lung cancer (NSCLC) continues to evolve expeditiously. Objectives This …
[HTML][HTML] Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
JS Ju, ACC Huang, PH Tung, CH Huang, TH Chiu… - Scientific Reports, 2023 - nature.com
Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation
is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR …
is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR …